This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Vincent A. Fulginiti, MD; John E. Lewy, MD

JAMA. 1993;270(2):246-248.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In the last two decades, remarkable progress has been made in our understanding of the etiology, pathogenesis, and basic molecular processes that result in disease. Cystic fibrosis is the most common lethal gene in our population, occurring in the carrier state in one person of every 20 to 25, and resulting in one in 2500 births of a child with the disease. The defect has now been clearly identified as a mutation of a specific gene, the cystic fibrosis transmembrane regulator (CFTR) gene, on chromosome 7.¹ The most common mutation results in a protein defective in phenylalanine at position 508, referred to as F508; in addition, more than 120 other mutations have been identified. Variance in the mutation does result in some phenotypic variation, but concordance for F508 leads to both pancreatic deficiency and pulmonary disease.

The CFTR defect leads to altered transport of sodium and chloride through the . . . [Full Text PDF of this Article]

Author Affiliations
University of Colorado Medical Center, Denver; Tulane University School of Medicine, New Orleans, La

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?